Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Betta Pharmaceuticals Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Guangdong Association of Clinical Trials
Betta Pharmaceuticals Co., Ltd.
Zhejiang Cancer Hospital
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.